It has been demonstrated that reduced activity of the anti-inflammatory HSP70 pathway correlates with nonalcoholic fatty liver disease (NAFLD) progression and with markers of oxidative stress in the obese patient, paralleled by similar reductions in HSF1 and insulin resistance [35]. Here, HSF1 is linked to metabolic dysfunction-associated steatotic liver disease.